AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28815282 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 μg/day calcidiol
Number of subjects: 87
Study 28815282 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 μg/day calcidiol
Number of subjects: 87
Study 28815282 — intervention group
Group type: EXPERIMENTAL
Intervention: 125 μg/week calcidiol
Number of subjects: 87
Study 28815282 — intervention group
Group type: EXPERIMENTAL
Intervention: All dosages of calcidiol
Number of subjects: 87
Study 25422394 — intervention group
Group type: EXPERIMENTAL
Intervention: Water treatment
Number of subjects: 499
Study 25422394 — intervention group
Group type: EXPERIMENTAL
Intervention: Sanitation and latrine improvements
Number of subjects: 499
Study 25422394 — intervention group
Group type: EXPERIMENTAL
Intervention: Handwashing with soap
Number of subjects: 499
Study 25422394 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of all three interventions
Number of subjects: 499
Study 23742346 — intervention group
Group type: EXPERIMENTAL
Intervention: Facade insulation measures
Number of subjects: 0
Study 23742346 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 16446335 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured multidisciplinary intervention (eight 90-minute sessions)
Number of subjects: 103
Study 16446335 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 103
Study 15089797 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes nurse educational programme (DN group)
Number of subjects: 54
Study 15089797 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC group)
Number of subjects: 54
Study 15089797 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups at 18 months
Number of subjects: 54
Study 11254020 — intervention group
Group type: EXPERIMENTAL
Intervention: Inositol (12 g)
Number of subjects: 24
Study 11254020 — intervention group
Group type: COMPARATOR
Intervention: Placebo (D-glucose)
Number of subjects: 24
Study 9273228 — intervention group
Group type: EXPERIMENTAL
Intervention: Noise exposure (over 90 dB intensity)
Number of subjects: 2599
Study 9273228 — intervention group
Group type: COMPARATOR
Intervention: Control group (not exposed to noise)
Number of subjects: 2599
Study 1622644 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (40 mg daily for 2 or 5 years)
Number of subjects: 1347
Study 1622644 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 1347
Study 6469811 — intervention group
Group type: EXPERIMENTAL
Intervention: Humidified room-temperature air containing 0.5 ppm SO2
Number of subjects: 7
Study 6469811 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold dry air
Number of subjects: 7
Study 6469811 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold dry air containing 0.5 ppm SO2
Number of subjects: 7
Study 31282542 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole (100 mg 4 times a day)
Number of subjects: 40
Study 31282542 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 31322200 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirulina, curcumin, and Boswellia supplement
Number of subjects: 34
Study 31322200 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 28425818 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-dose priming and booster (3 + 1)
Number of subjects: 300
Study 28425818 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-dose priming and booster (2 + 1)
Number of subjects: 300
Study 28425818 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-dose priming without booster (3 + 0)
Number of subjects: 300
Study 26521589 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) at Neiguan (PC 6) 30 min before operation until the end of operation.
Number of subjects: 50
Study 26521589 — intervention group
Group type: COMPARATOR
Intervention: Control group (no electroacupuncture).
Number of subjects: 50
Study 23398709 — intervention group
Group type: EXPERIMENTAL
Intervention: Participatory behavior‐based injury prevention approach integrated with safety culture initiatives
Number of subjects: 16
Study 23398709 — intervention group
Group type: EXPERIMENTAL
Intervention: Owner/manager led constructive dialogue meetings with workers
Number of subjects: 16
Study 23398709 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention enterprises
Number of subjects: 16
Study 23398709 — intervention group
Group type: COMPARATOR
Intervention: Comparison enterprises
Number of subjects: 16
Study 23398709 — intervention group
Group type: EXPERIMENTAL
Intervention: Both intervention and comparison enterprises
Number of subjects: 16
Study 21481274 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac-Diabetes Self-Management Program (including three face-to-face sessions, telephone and text messaging follow-up)
Number of subjects: 30
Study 21481274 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 30
Study 19249750 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline (2 mg/day)
Number of subjects: 20
Study 19249750 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 16482753 — intervention group
Group type: EXPERIMENTAL
Intervention: Morbidity-last group (questions about the wife's disease first)
Number of subjects: 76
Study 16482753 — intervention group
Group type: COMPARATOR
Intervention: Morbidity-first group (respondent's current wellbeing first)
Number of subjects: 76
Study 12617375 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent pneumatic compression (IPC) combined with standard physiotherapy (10 cycles of 3 minutes with a peak of 40 mmHg)
Number of subjects: 23
Study 12617375 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment (sham short-wave therapy for 30 minutes) combined with conventional physiotherapy
Number of subjects: 23
Study 10875524 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental Sorting Task for Children (STC)
Number of subjects: 64
Study 10875524 — intervention group
Group type: COMPARATOR
Intervention: Modified Card Sorting Test (adult sorting task)
Number of subjects: 64
Study 10875524 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilot study of children with idiopathic or cryptogenic epilepsy
Number of subjects: 64
Study 8699499 — intervention group
Group type: EXPERIMENTAL
Intervention: Couple therapy
Number of subjects: 2
Study 1394828 — intervention group
Group type: EXPERIMENTAL
Intervention: Adriamycin
Number of subjects: 777
Study 1394828 — intervention group
Group type: EXPERIMENTAL
Intervention: Epodyl
Number of subjects: 777
Study 1394828 — intervention group
Group type: COMPARATOR
Intervention: Transurethral resection alone
Number of subjects: 777
Study 1394828 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-epirubicin
Number of subjects: 777
Study 1394828 — intervention group
Group type: COMPARATOR
Intervention: Sterile water
Number of subjects: 777
Study 4074992 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive control methods through a detailed booklet (group 1)
Number of subjects: 30
Study 4074992 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive control methods taught orally (group 2)
Number of subjects: 30
Study 4074992 — intervention group
Group type: COMPARATOR
Intervention: Attention-placebo control group (group 3)
Number of subjects: 30
Study 31697747 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated left/right Kocher-Monro trajectory
Number of subjects: 132
Study 31697747 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 132
Study 28722030 — intervention group
Group type: EXPERIMENTAL
Intervention: legume-based TLC diet
Number of subjects: 31
Study 28722030 — intervention group
Group type: COMPARATOR
Intervention: legume-free TLC diet
Number of subjects: 31
Study 27048747 — intervention group
Group type: EXPERIMENTAL
Intervention: MVC + 2 N(t)RTI
Number of subjects: 395
Study 27048747 — intervention group
Group type: EXPERIMENTAL
Intervention: MVC + PI/r
Number of subjects: 395
Study 27048747 — intervention group
Group type: COMPARATOR
Intervention: Control (current combination antiretroviral therapy)
Number of subjects: 395
Study 25149882 — intervention group
Group type: EXPERIMENTAL
Intervention: INSURE method (Intubation, Surfactant administration and extubation)
Number of subjects: 0
Study 25149882 — intervention group
Group type: COMPARATOR
Intervention: Conventional Mechanical Ventilation (CMV)
Number of subjects: 0
Study 22078337 — intervention group
Group type: EXPERIMENTAL
Intervention: Trigone-including injections of 500 U abobotulinumtoxinA diluted to 20ml
Number of subjects: 22
Study 22078337 — intervention group
Group type: COMPARATOR
Intervention: Trigone-sparing injections of 500 U abobotulinumtoxinA diluted to 20ml
Number of subjects: 22
Study 22078337 — intervention group
Group type: EXPERIMENTAL
Intervention: Trigone-including injections
Number of subjects: 22
Study 22078337 — intervention group
Group type: EXPERIMENTAL
Intervention: Trigone-including and trigone-sparing injections
Number of subjects: 22
Study 20008446 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 0
Study 20008446 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20008446 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 0
Study 20008446 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine
Number of subjects: 0
Study 17617524 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative surgery (unilateral salpingo-oophorectomy or cystectomy) for stage I disease
Number of subjects: 0
Study 17617524 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical surgery (total abdominal hysterectomy, bilateral salpingo-oophorectomy, etc.) for advanced-stage disease or completed childbearing
Number of subjects: 0
Study 16116013 — intervention group
Group type: EXPERIMENTAL
Intervention: Lightwand (Intubating Lighted Stylet)
Number of subjects: 36
Study 16116013 — intervention group
Group type: COMPARATOR
Intervention: Macintosh laryngoscopy
Number of subjects: 36
Study 16116013 — intervention group
Group type: COMPARATOR
Intervention: GlideScope
Number of subjects: 36
Study 11821289 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum IL-6
Number of subjects: 130
Study 11821289 — intervention group
Group type: EXPERIMENTAL
Intervention: PF TNF-alpha
Number of subjects: 130
Study 11821289 — intervention group
Group type: COMPARATOR
Intervention: Control group (tubal ligation or reanastomosis)
Number of subjects: 130
Study 10029400 — intervention group
Group type: EXPERIMENTAL
Intervention: Pacifier with sucrose
Number of subjects: 122
Study 10029400 — intervention group
Group type: EXPERIMENTAL
Intervention: Pacifier with sterile water
Number of subjects: 122
Study 10029400 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone positioning
Number of subjects: 122
Study 7627386 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine, 100 mg IV twice a day for two days, followed by 150 mg orally twice a day for three days
Number of subjects: 23
Study 7627386 — intervention group
Group type: COMPARATOR
Intervention: No ranitidine
Number of subjects: 23
Study 1783090 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry air during exercise followed by dry air after exercise (DD)
Number of subjects: 12
Study 1783090 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry air during exercise followed by humid air after exercise (DH)
Number of subjects: 12
Study 1783090 — intervention group
Group type: EXPERIMENTAL
Intervention: Humid air during exercise followed by dry air after exercise (HD)
Number of subjects: 12
Study 1783090 — intervention group
Group type: EXPERIMENTAL
Intervention: Humid air during exercise followed by humid air after exercise (HH)
Number of subjects: 12
Study 1783090 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery in dry air after exercise
Number of subjects: 12
Study 1783090 — intervention group
Group type: COMPARATOR
Intervention: Recovery in humid air after exercise
Number of subjects: 12
Study 7240598 — intervention group
Group type: EXPERIMENTAL
Intervention: Unmodified ragweed extract (RW)
Number of subjects: 67
Study 7240598 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutaraldehyde polymer of ragweed extract (PRW)
Number of subjects: 67
Study 7240598 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 30980561 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided Tissue Regeneration (GTR)
Number of subjects: 16
Study 30980561 — intervention group
Group type: COMPARATOR
Intervention: Open Flap Debridement (OFD)
Number of subjects: 16
Study 30980561 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (OFD and GTR)
Number of subjects: 16
Study 28536723 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-way SMS medication reminders
Number of subjects: 47
Study 28536723 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 47
Study 26384233 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose of alcohol intake (0.4 g/kg)
Number of subjects: 12
Study 26384233 — intervention group
Group type: COMPARATOR
Intervention: Placebo intake
Number of subjects: 12
Study 26384233 — intervention group
Group type: EXPERIMENTAL
Intervention: Focus not on alcohol condition
Number of subjects: 12
Study 26384233 — intervention group
Group type: EXPERIMENTAL
Intervention: Explicit judgment on beverage-related cues
Number of subjects: 12
Study 23690322 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextrose prolotherapy
Number of subjects: 90
Study 23690322 — intervention group
Group type: COMPARATOR
Intervention: Saline injection
Number of subjects: 90
Study 23690322 — intervention group
Group type: COMPARATOR
Intervention: At-home exercise
Number of subjects: 90
Study 21346338 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised body temperature dialysis (HD(ind))
Number of subjects: 11
Study 21346338 — intervention group
Group type: COMPARATOR
Intervention: Haemodialysis at 37°C (HD(37))
Number of subjects: 11
Study 20137473 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 microg recombination yeast hepatitis B vaccine (3 doses at 0 month, 1st month, 6th month)
Number of subjects: 568
Study 20137473 — intervention group
Group type: COMPARATOR
Intervention: Control group (age > 18)
Number of subjects: 568
Study 18297891 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation (usually in combination with folic acid)
Number of subjects: 0
Study 18297891 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal iron supplementation
Number of subjects: 0
Study 18297891 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for anemia and targeted supplementation
Number of subjects: 0
Study 18297891 — intervention group
Group type: EXPERIMENTAL
Intervention: Withholding iron supplementation until treatment schedule is complete
Number of subjects: 0
Study 14711565 — intervention group
Group type: EXPERIMENTAL
Intervention: Follicle aspiration set (FAS)
Number of subjects: 300
Study 14711565 — intervention group
Group type: COMPARATOR
Intervention: Standard needle (Echotip)
Number of subjects: 300
Study 11476462 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine 5 mg q.d.
Number of subjects: 62
Study 11476462 — intervention group
Group type: COMPARATOR
Intervention: Oxatomide 25 mg q.d.
Number of subjects: 62
Study 9170765 — intervention group
Group type: EXPERIMENTAL
Intervention: TP (treatment-plan-related tasks)
Number of subjects: 0
Study 9170765 — intervention group
Group type: COMPARATOR
Intervention: UA (urine samples testing negative for illicit drugs)
Number of subjects: 0
Study 9170765 — intervention group
Group type: COMPARATOR
Intervention: STD (standard treatment)
Number of subjects: 0
Study 7711089 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief intervention (BI), a one-session motivational interview
Number of subjects: 121
Study 7711089 — intervention group
Group type: COMPARATOR
Intervention: Non-intervention control condition (NIC)
Number of subjects: 121
Study 2906783 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine 40 mg
Number of subjects: 286
Study 2906783 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg
Number of subjects: 286
Study 2906783 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 286
Study 29648514 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 × 50 min/wk of supervised center‐based walking (n = 14)
Number of subjects: 27
Study 29648514 — intervention group
Group type: COMPARATOR
Intervention: No-exercise (n = 13)
Number of subjects: 27
Study 29648514 — intervention group
Group type: COMPARATOR
Intervention: Comparison between groups
Number of subjects: 27
Study 29648514 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 27
Study 25802346 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced care management with motivational and parent management techniques
Number of subjects: 156
Study 25802346 — intervention group
Group type: COMPARATOR
Intervention: Basic collaborative care management
Number of subjects: 156
Study 23063633 — intervention group
Group type: EXPERIMENTAL
Intervention: 320 mg daily of saw palmetto extract
Number of subjects: 357
Study 23063633 — intervention group
Group type: EXPERIMENTAL
Intervention: 640 mg daily of saw palmetto extract
Number of subjects: 357
Study 23063633 — intervention group
Group type: EXPERIMENTAL
Intervention: 960 mg daily of saw palmetto extract
Number of subjects: 357
Study 23063633 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 357
Study 20650382 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 degrees stylet
Number of subjects: 120
Study 20650382 — intervention group
Group type: COMPARATOR
Intervention: 60 degrees stylet
Number of subjects: 120
Study 18065796 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetate-Free Biofiltration with constant potassium (2.5 mEq/l) (AFB)
Number of subjects: 30
Study 18065796 — intervention group
Group type: COMPARATOR
Intervention: Acetate-Free Biofiltration with decreasing intra-HD potassium (AFBK)
Number of subjects: 30
Study 17239094 — intervention group
Group type: EXPERIMENTAL
Intervention: A‐CPVA (aggressive circumferential pulmonary vein ablation) group, n = 50
Number of subjects: 100
Study 17239094 — intervention group
Group type: COMPARATOR
Intervention: M‐CPVA (modified circumferential pulmonary vein ablation) group, n = 50
Number of subjects: 100
Study 12972523 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine 1,250 mg/m2 IV on days 1 and 8, and cisplatin 100 mg/m2 IV on day 1 (GC arm)
Number of subjects: 80
Study 12972523 — intervention group
Group type: COMPARATOR
Intervention: Irinotecan 150 mg/m2 IV on day 1 and cisplatin 80 mg/m2 IV on day 1 (IC arm)
Number of subjects: 80
Study 10358993 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific therapy and ultrasonic treatment (44 KHz, amplitude 2 microm to the paravertebral region and PT zones)
Number of subjects: 50
Study 10358993 — intervention group
Group type: COMPARATOR
Intervention: Specific therapy only
Number of subjects: 50
Study 8665055 — intervention group
Group type: EXPERIMENTAL
Intervention: rhDNase 2.5 mg in 2.5 ml excipient twice a day (n = 43)
Number of subjects: 80
Study 8665055 — intervention group
Group type: COMPARATOR
Intervention: 2.5 ml excipient alone twice daily (n = 37)
Number of subjects: 80
Study 8665055 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups (rhDNase and control)
Number of subjects: 80
Study 1874198 — intervention group
Group type: EXPERIMENTAL
Intervention: Frusemide 0.5 mg kg‐1 at the onset of hypotension (Group F)
Number of subjects: 25
Study 1874198 — intervention group
Group type: COMPARATOR
Intervention: Labetalol induced hypotension in Groups E and I
Number of subjects: 25
Study 1874198 — intervention group
Group type: COMPARATOR
Intervention: Labetalol induced hypotension in Group F
Number of subjects: 25
Study 1874198 — intervention group
Group type: EXPERIMENTAL
Intervention: Frusemide (Group F)
Number of subjects: 25
Study 6352599 — intervention group
Group type: EXPERIMENTAL
Intervention: Azlocillin (18 g/day, intravenously)
Number of subjects: 49
Study 6352599 — intervention group
Group type: COMPARATOR
Intervention: Gentamicin (3 to 5 mg/kg/day, intramuscularly)
Number of subjects: 49
Study 6352599 — intervention group
Group type: EXPERIMENTAL
Intervention: Azlocillin
Number of subjects: 49
Study 6352599 — intervention group
Group type: COMPARATOR
Intervention: Gentamicin
Number of subjects: 49
Study 3894470 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced cost sharing (coinsurance rate falls from 95% to 0%)
Number of subjects: 0
Study 3894470 — intervention group
Group type: EXPERIMENTAL
Intervention: More generous coverage in the first year
Number of subjects: 0
Study 29713850 — intervention group
Group type: EXPERIMENTAL
Intervention: Experience Focussed Counselling (EFC)
Number of subjects: 25
Study 29713850 — intervention group
Group type: COMPARATOR
Intervention: Treatment As Usual
Number of subjects: 25
Study 27402237 — intervention group
Group type: EXPERIMENTAL
Intervention: Best Endovascular Therapy
Number of subjects: 2100
Study 27402237 — intervention group
Group type: COMPARATOR
Intervention: Best Surgical Therapy
Number of subjects: 2100
Study 24097439 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel plus aspirin (dual therapy)
Number of subjects: 5045
Study 24097439 — intervention group
Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 5045
Study 22803968 — intervention group
Group type: EXPERIMENTAL
Intervention: Terumo Capiox FX25 (Group-T)
Number of subjects: 80
Study 22803968 — intervention group
Group type: COMPARATOR
Intervention: Sorin Synthesis (Group-S)
Number of subjects: 80
Study 20160062 — intervention group
Group type: EXPERIMENTAL
Intervention: IDH1 mutations
Number of subjects: 159
Study 20160062 — intervention group
Group type: COMPARATOR
Intervention: PCV chemotherapy
Number of subjects: 159
Study 18657891 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum phosphorus level greater than 6 mg/dL
Number of subjects: 1846
Study 18657891 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum calcium level greater than 11 mg/dL
Number of subjects: 1846
Study 18657891 — intervention group
Group type: EXPERIMENTAL
Intervention: Ca x P product greater than 50 mg(2)/dL(2)
Number of subjects: 1846
Study 18657891 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphorus, calcium, and Ca x P product values
Number of subjects: 1846
Study 18657891 — intervention group
Group type: EXPERIMENTAL
Intervention: Intact parathyroid hormone levels
Number of subjects: 1846
Study 15820416 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan (100 mg)
Number of subjects: 15
Study 15820416 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 12593498 — intervention group
Group type: COMPARATOR
Intervention: Acute myocardial infarction (AMI)
Number of subjects: 59